Last Capital Raise resulted in nothing more than James getting a 10% salary bump.
As a long term holder with a average buy price of 20c+ I'm frankly disgusted with how badly James has run this company. Firstly, publicly stating non-dilutive funding would be pursued through their parent company Noxopharm, then completely mismanaging the pandemic. long after other companies pulled out of China he hung in there and took a huge raise based on the companies inability to spend any of the money while not being physically able to pursue further research due to constant lockdowns, and more recently pre-emptively employing (presumably still on the books) a sales rep from Pfizer.
And then somehow missed a fatal flaw in their PCSK9 inhibitor.
Shareholders should be outraged, not talking themselves into complacently and wishful thinking.
NYR Price at posting:
9.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)